| Literature DB >> 30339665 |
Mari Kinoshita1, Shinichi Oka1.
Abstract
The present study aimed to identify factors associated with retention in HIV/AIDS care among migrant patients who visited the outpatient clinic of the AIDS Clinical Center, National Center for Global Health and Medicine in Tokyo, Japan. We reviewed the records of 551 selected (78 non-Japanese and 473 Japanese) patients who started visiting our clinic between 2011 and 2014. A total of 390 patients (70.8%: 38 non-Japanese and 352 Japanese) continued their visits during the study: from the date of their first visit to the end of 2015. The difference in retention rate was not significant (Incidence Rate Ratio (IRR) = 0.89, p = 0.27), but the loss-to-follow-up cases were considerably high among non-Japanese patients (n = 13, Incidence rate (IR) = 24.6 per 100,000 person-days, IRR = 3.65, p<0.01 after adjusting for time since diagnosis). The results showed, nevertheless, that there was no apparent association between retention and factors peculiar to non-Japanese. Twelve out of thirteen lost-to-follow-up non-Japanese patients held legal status to reside in Japan and were eligible for public health services. Nine had limited fluency in Japanese language, and six used alternative verbal communication. Further studies are needed to identify the factors responsible for the high dropout rate and to improve the care of migrant patients living with HIV/AIDS.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30339665 PMCID: PMC6195273 DOI: 10.1371/journal.pone.0205184
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Flow diagram of patient selection.
Baseline characteristics of study population, 2011–2014.
| Non-Japanese (n = 78) | Japanese (n = 473) | ||||
|---|---|---|---|---|---|
| Characteristics | n | % | n | % | |
| Overall | |||||
| 78 | 14.2 | 473 | 85.8 | - | |
| Age | |||||
| 0–19 | 1 | 1.3 | 5 | 1.1 | 0.877 |
| 20–29 | 23 | 26.5 | 109 | 23.0 | 0.499 |
| 30–39 | 30 | 38.5 | 188 | 39.8 | 0.828 |
| 40–49 | 19 | 24.4 | 124 | 26.2 | 0.737 |
| 50–59 | 5 | 6.4 | 32 | 6.8 | 0.896 |
| 60+ | 0 | 0.0 | 15 | 3.2 | - |
| Gender | |||||
| Male | 63 | 81.7 | 459 | 97.0 | <0.001 |
| Female | 15 | 18.3 | 14a | 3.0 | <0.001 |
| Year of first visit | |||||
| 2011 | 22 | 30.5 | 122 | 25.8 | 0.383 |
| 2012 | 15 | 18.3 | 131 | 27.7 | 0.081 |
| 2013 | 21 | 25.6 | 116 | 24.5 | 0.835 |
| 2014 | 20 | 25.6 | 104 | 22.0 | 0.481 |
| Time since HIV diagnosis | |||||
| < 1 year | 53 | 68.0 | 394 | 83.3 | <0.001 |
| 1 to 5 year | 14 | 18.0 | 52 | 11.0 | 0.779 |
| > 5 year | 11 | 14.0 | 27 | 5.7 | 0.007 |
| On ART | |||||
| Yes | 20 | 25.6 | 53 | 11.2 | <0.001 |
| No | 58 | 74.4 | 420 | 88.8 | <0.001 |
| CD4+ cell count | |||||
| < 200 /μl | 19 | 25.6 | 152 | 32.1 | 0.251 |
| ≥ 200 /μl | 59 | 74.4 | 321 | 67.9 | 0.251 |
| HIV-1 RNA | |||||
| < 1000 copies/ml | 21 | 25.6 | 52 | 11.0 | <0.001 |
| ≥ 1000 copies/ml | 57 | 74.4 | 421 | 89.0 | <0.001 |
| HIV stage | |||||
| AIDS | 11 | 14.1 | 80 | 16.9 | 0.536 |
| AC | 47 | 60.3 | 356 | 75.3 | 0.006 |
| Symptomatic | 8 | 10.3 | 23 | 4.9 | 0.055 |
| Others | 12 | 15.4 | 14 | 3.0 | <0.001 |
All data are as of first visit.
Female data include a Male-To-Female transgender.
AC stands for Asymptomatic Careers.
Profiles of non-Japanese participants (n = 78).
| n | % | |
|---|---|---|
| Region of origin | ||
| Asia | 37 | 47.4 |
| Africa | 16 | 20.5 |
| North America | 9 | 11.5 |
| Latin America | 7 | 9.0 |
| Europe | 6 | 7.7 |
| Oceania | 3 | 3.9 |
| National Health Insurance | ||
| Eligible | 71 | 91.0 |
| Not Eligible | 7 | 9.0 |
| Japanese Language Proficiency | ||
| Fluent/Native | 21 | 26.9 |
| Conversation | 27 | 34.6 |
| Poor/Words | 29 | 37.2 |
| Unknown | 1 | 1.3 |
| Alternative Communication with Hospital Staff | ||
| Use of English | 47 | 59.5 |
| Use of Interpreter | 6 | 7.6 |
Follow-up outcome between non-Japanese and Japanese patients.
| Non-Japanese (n = 78) | Japanese (n = 473) | IRR of | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Characteristics | Retained | Referral | Police | Death | LTF | Retained | Referred | Police | Death | LTF | |||
| person-days | Count (IR per 100,000 person-days) | person-days | Count (IR per 100,000 person-days) | ||||||||||
| Overall | |||||||||||||
| 52,872 | 38 (71.9) | 27 (51.1) | 0 (0.0) | 0 (0.0) | 13 (24.6) | 439,456 | 352 (80.1) | 97 (22.1) | 3 (0.0) | 3 (0.0) | 18 (4.1) | 6.0 | |
| Age, years old | |||||||||||||
| 0–29 | 13,002 | 6 (46.2) | 14 (107.7) | - | - | 4 (30.8) | 89,161 | 70 (78.5) | 36 (40.4) | 0 (0.0) | 0 (0.0) | 8 (9.0) | 3.43 |
| 30–39 | 15,641 | 12 (76.7) | 12 (76.7) | - | - | 6 (38.4) | 174,887 | 135 (77.2) | 45 (25.7) | 2 (1.1) | 0 (0.0) | 6 (3.4) | 11.2 |
| 40–49 | 19,924 | 16 (80.3) | 1 (5.0) | - | - | 2 (10.0) | 123,830 | 108 (87.2) | 11 (8.9) | 1 (0.0) | 1 (0.0) | 3 (2.4) | 4.1 |
| 50+ | 4,305 | 4 (92.9) | 0 (0.0) | - | - | 1 (23.2) | 51,578 | 39 (75.6) | 5 (9.7) | 0 (0.0) | 2 (3.9) | 1 (1.9) | 12.0 |
| Gender | |||||||||||||
| Male | 39,002 | 30 (76.9) | 22 (56.4) | - | - | 11 (28.2) | 423,793 | 339 (80.0) | 97 (22.9) | 3 (0.0) | 3 (0.0) | 17 (4.0) | 7.0 |
| Female | 13,870 | 8 (57.7) | 5 (36.1) | - | - | 2 (14.4) | 15,663 | 13 (83.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (6.4) | 2.3 |
| Year of first visit | |||||||||||||
| 2011 | 24,376 | 11 (45.1) | 7 (28.7) | - | - | 4 (16.4) | 168,456 | 90 (53.4) | 25 (14.8) | 1 (0.0) | 2 (1.2) | 4 (2.4) | 6.9 |
| 2012 | 11,544 | 7 (60.6) | 6 (52.0) | - | - | 2 (17.3) | 133,422 | 92 (69.0) | 32 (24.0) | 0 (0.0) | 1 (0.0) | 6 (4.5) | 3.9 |
| 2013 | 8,666 | 7 (80.8) | 8 (92.3) | - | - | 6 (69.2) | 87,724 | 86 (98.0) | 25 (28.5) | 1 (1.1) | 0 (0.0) | 4 (4.6) | 15.2 |
| 2014 | 8,286 | 13 (156.9) | 6 (72.4) | - | - | 1 (12.1) | 49,854 | 84 (168.5) | 15 (30.1) | 1 (2.0) | 0 (0.0) | 4 (8.0) | 1.5 |
| Time since diagnosis | |||||||||||||
| 0–1 year | 37,162 | 29 (78.0) | 19 (51.1) | - | - | 5 (13.5) | 371,945 | 302 (81.2) | 74 (19.9) | 1 (0.0) | 2 (0.0) | 15 (4.3) | 3.3 |
| 1–5 years | 9,395 | 5 (53.2) | 7 (74.5) | - | - | 2 (21.3) | 45,233 | 32 (70.7) | 16 (35.4) | 2 (4.4) | 1 (2.2) | 1 (2.2) | 9.6 |
| 5 years+ | 6,315 | 4 (63.3) | 1 (15.8) | - | - | 6 (95.0) | 22,278 | 18 (80.8) | 7 (31.4) | 0 (0.0) | 0 (0.0) | 2 (9.0) | 10.6 |
| On ART | |||||||||||||
| Yes | 9,549 | 5 (76.2) | 9 (94.3) | - | - | 6 (62.8) | 45,079 | 36 (79.9) | 12 (26.6) | 2 (4.4) | 0 (0.0) | 3 (6.7) | 9.4 |
| No | 43,323 | 33 (52.4) | 18 (41.6) | - | - | 7 (16.2) | 394,377 | 316 (80.1) | 85 (21.6) | 1 (0.0) | 3 (0.0) | 15 (3.8) | 4.3 |
| CD4+ cell, count//μl | |||||||||||||
| < 200 | 15,018 | 15 (99.9) | 2 (13.3) | - | - | 2 (13.3) | 146,988 | 123 (83.7) | 23 (15.7) | 0 (0.0) | 0 (0.0) | 6 (4.1) | 3.3 |
| ≥ 200 | 37,854 | 23 (60.8) | 25 (66.0) | - | - | 11 (29.1) | 292,468 | 229 (78.3) | 74 (25.3) | 3 (1.0) | 3 (1.0) | 12 (3.2) | 7.1 |
| HIV-1 RNA, copies/ml | |||||||||||||
| < 1000 | 11,670 | 7 (60.0) | 9 (77.1) | - | - | 5 (42.8) | 46,207 | 35 (75.8) | 12 (26.0) | 2 (4.3) | 0 (0.0) | 3 (6.5) | 6.6 |
| ≥ 1000 | 41,202 | 31 (75.2) | 18 (43.7) | - | - | 8 (19.4) | 393,249 | 317 (80.6) | 85 (21.6) | 1 (0.0) | 3 (0.0) | 15 (3.8) | 5.1 |
| HIV stage | |||||||||||||
| AIDS | 7,980 | 8 (100.3) | 2 (25.1) | - | - | 1 (12.5) | 82,204 | 260 (81.5) | 78 (9.7) | 2 (1.2) | 2 (1.2) | 3 (3.7) | 3.4 |
| AC | 29,920 | 20 (66.8) | 19 (63.5 | - | - | 8 (26.7) | 337,746 | 67 (77.0) | 8 (23.1) | 1 (0.0) | 1 (0.0) | 14 (4.2) | 6.5 |
| Symptomatic | 9,316 | 6 (64.4) | 0 (0.0) | - | - | 2 (21.5) | 14,855 | 20 (134.6) | 3 (20.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | NA |
| Others | 5,656 | 4 (70.7) | 6 (106.1) | - | - | 2 (35.4) | 4,651 | 5 (107.5) | 8 (172.0) | 0 (0.0) | 0 (0.0) | 1 (2.2) | 1.6 |
Characteristics as of the first visit. Japanese Female data include a Male-To-Female transgender.
IR stands for Incidence Rate per 100,000 person-days. IRR stands for Incident Rate Ratio. AC stands for Asymptomatic Carriers.
* p<0.05
** p<0.01.
Results of Poisson regression analyses (n = 551).
| Univariable Analysis | Multivariable Model (A) | Multivariable Model (B) | ||||
|---|---|---|---|---|---|---|
| Variables | IRR (95%CI) | |||||
| Non-Japanese | 4.38 (2.15–8.94) | <0.01 | 3.60 (1.72–7.51) | <0.01 | 3.65 (1.76–7.59) | <0.01 |
| Age at enrolment | 0.97 (0.93–1.00) | 0.11 | ||||
| Male gender | 0.52 (0.16–1.70) | 0.28 | ||||
| Year of enrolment | 0.96 (0.70–1.32) | 0.80 | ||||
| On ART | 2.68 (1.23–5.82) | 0.01 | 1.16 (0.37–3.68) | 0.79 | ||
| CD4+ cell count≥200/μl | 1.29 (0.58–2.89) | 0.53 | ||||
| HIV-1 RNA>1000 copies/ml | 0.44 (0.20–0.98) | 0.05 | 0.96 (0.33–2.81) | 0.95 | ||
| Time since HIV diagnosis, year | 1.37 (1.16–1.61) | <0.01 | 1.26 (1.03–1.55) | 0.03 | 1.29 (1.09–1.53) | <0.01 |
All variables with a p<0.1 in the univariable analyses were submitted in multivariable model (A). Likewise, all variables with a p<0.1 in model (A) were submitted in the model (B)
Profiles of the non-Japanese patients who were lost-to-follow-up during the study period (n = 13).
| Case | Time to attrition | Gender | CD4+ count/μl | Japanese language | English use | Interpreter use | Disclosure of HIV | Legal status | Region of origin | ART in |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 1 | M | 344 | Conversation | Yes | No | Yes | Yes | Asia | Subsidized |
| 2 | 7 | M | 341 | Conversation | Yes | No | None | Yes | Oceania | Free |
| 3 | 29 | M | 282 | Conversation | Yes | Yes | Yes | Yes | Latin America | Free |
| 4 | 29 | M | 637 | Fluent | No | No | Unknown | Yes | Latin America | Free |
| 5 | 32 | F | 423 | Words only | Yes | No | None | Yes | Africa | Free |
| 6 | 43 | M | 181 | Words only | No | No | None | No | Africa | No |
| 7 | 85 | M | 275 | Poor | No | No | Yes | Yes | Africa | No |
| 8 | 107 | M | 373 | Fluent | No | No | None | Yes | Asia | Free |
| 9 | 135 | M | 322 | Poor | Yes | No | None | Yes | North America | Conditional |
| 10 | 482 | M | 291 | Native | No | No | Yes | Yes | Asia | Subsidized |
| 11 | 644 | F | 773 | Conversation | No | No | Yes | Yes | Asia | Subsidized |
| 12 | 680 | M | 280 | Conversation | Yes | No | No | Yes | Europe | Free |
| 13 | 1180 | M | 135 | Fluent | No | No | Yes | Yes | Asia | Subsidized |
1)WHO; Countries offering free access to HIV treatment; Developing Countries & Free Access Fact Sheet; December 2005.
2)WHO; Democratic Republic of the Congo; Summary Country Profile for HIV/AIDS Treatment Scale-Up; December 2005.
3)UNAIDS; Access to antiretroviral therapy in Africa; status report on progress towards the 2015 targets; 2013.